Matches in SemOpenAlex for { <https://semopenalex.org/work/W4362545247> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W4362545247 abstract "<div>Abstract<p>Most patients with HER2-positive breast or gastric cancer exhibit primary or acquired resistance to trastuzumab emtansine (T-DM1), and such patients may have limited therapeutic options. XMT-1522 is a novel anti-HER2 antibody–drug conjugate. We compared XMT-1522 to T-DM1 in preclinical models. The effects of XMT-1522 and T-DM1 on cell survival and apoptosis were compared in six HER2-positive breast cancer or gastric cancer cell lines, of which three lines were T-DM1–sensitive (N-87, OE-19, JIMT-1) and three T-DM1–resistant (RN-87, ROE-19, SNU-216). We compared these agents also in the HER2-negative breast cancer cell line MCF-7, and in mouse RN-87 and JIMT-1 xenograft models. Cell survival was assessed using the AlamarBlue method and apoptosis with the Caspase-Glo 3/7 method. XMT-1522 inhibited the growth of all six HER2-positive cell lines. The proportions of cells that survived XMT-1522 treatment were smaller as compared with T-DM1, particularly in the T-DM1–resistant cell lines. XMT-1522 induced more cell apoptosis compared with T-DM1. While RN-87 and JIMT-1 xenograft tumors progressed on T-DM1 treatment, all tumors responded to XMT-1522, and all but one tumor disappeared during the XMT-1522 treatment. XMT-1522 had a strong antitumor effect on RN-87 and JIMT-1 xenografts that progressed on T-DM1. We conclude that XMT-1522 was effective in HER2-positive breast cancer and gastric cancer cell lines resistant to T-DM1, and in xenograft models resistant to T-DM1. The results support the testing of XMT-1522 in clinical trials in patients with HER2-positive cancer.</p></div>" @default.
- W4362545247 created "2023-04-06" @default.
- W4362545247 creator A5003142554 @default.
- W4362545247 creator A5045081403 @default.
- W4362545247 creator A5047940272 @default.
- W4362545247 creator A5067202724 @default.
- W4362545247 creator A5068108014 @default.
- W4362545247 creator A5069828504 @default.
- W4362545247 creator A5079080628 @default.
- W4362545247 creator A5090618504 @default.
- W4362545247 date "2023-04-03" @default.
- W4362545247 modified "2023-09-30" @default.
- W4362545247 title "Data from A Novel Anti-HER2 Antibody–Drug Conjugate XMT-1522 for HER2-Positive Breast and Gastric Cancers Resistant to Trastuzumab Emtansine" @default.
- W4362545247 doi "https://doi.org/10.1158/1535-7163.c.6539571" @default.
- W4362545247 hasPublicationYear "2023" @default.
- W4362545247 type Work @default.
- W4362545247 citedByCount "0" @default.
- W4362545247 crossrefType "posted-content" @default.
- W4362545247 hasAuthorship W4362545247A5003142554 @default.
- W4362545247 hasAuthorship W4362545247A5045081403 @default.
- W4362545247 hasAuthorship W4362545247A5047940272 @default.
- W4362545247 hasAuthorship W4362545247A5067202724 @default.
- W4362545247 hasAuthorship W4362545247A5068108014 @default.
- W4362545247 hasAuthorship W4362545247A5069828504 @default.
- W4362545247 hasAuthorship W4362545247A5079080628 @default.
- W4362545247 hasAuthorship W4362545247A5090618504 @default.
- W4362545247 hasConcept C121608353 @default.
- W4362545247 hasConcept C126322002 @default.
- W4362545247 hasConcept C143998085 @default.
- W4362545247 hasConcept C159654299 @default.
- W4362545247 hasConcept C190283241 @default.
- W4362545247 hasConcept C203014093 @default.
- W4362545247 hasConcept C2777325958 @default.
- W4362545247 hasConcept C2778087150 @default.
- W4362545247 hasConcept C2779786085 @default.
- W4362545247 hasConcept C502942594 @default.
- W4362545247 hasConcept C530470458 @default.
- W4362545247 hasConcept C542903549 @default.
- W4362545247 hasConcept C55493867 @default.
- W4362545247 hasConcept C71924100 @default.
- W4362545247 hasConcept C86803240 @default.
- W4362545247 hasConcept C98274493 @default.
- W4362545247 hasConceptScore W4362545247C121608353 @default.
- W4362545247 hasConceptScore W4362545247C126322002 @default.
- W4362545247 hasConceptScore W4362545247C143998085 @default.
- W4362545247 hasConceptScore W4362545247C159654299 @default.
- W4362545247 hasConceptScore W4362545247C190283241 @default.
- W4362545247 hasConceptScore W4362545247C203014093 @default.
- W4362545247 hasConceptScore W4362545247C2777325958 @default.
- W4362545247 hasConceptScore W4362545247C2778087150 @default.
- W4362545247 hasConceptScore W4362545247C2779786085 @default.
- W4362545247 hasConceptScore W4362545247C502942594 @default.
- W4362545247 hasConceptScore W4362545247C530470458 @default.
- W4362545247 hasConceptScore W4362545247C542903549 @default.
- W4362545247 hasConceptScore W4362545247C55493867 @default.
- W4362545247 hasConceptScore W4362545247C71924100 @default.
- W4362545247 hasConceptScore W4362545247C86803240 @default.
- W4362545247 hasConceptScore W4362545247C98274493 @default.
- W4362545247 hasLocation W43625452471 @default.
- W4362545247 hasOpenAccess W4362545247 @default.
- W4362545247 hasPrimaryLocation W43625452471 @default.
- W4362545247 hasRelatedWork W1472101725 @default.
- W4362545247 hasRelatedWork W1963781110 @default.
- W4362545247 hasRelatedWork W2031947447 @default.
- W4362545247 hasRelatedWork W2076131513 @default.
- W4362545247 hasRelatedWork W2779597736 @default.
- W4362545247 hasRelatedWork W2885658945 @default.
- W4362545247 hasRelatedWork W2997835015 @default.
- W4362545247 hasRelatedWork W3109823528 @default.
- W4362545247 hasRelatedWork W3188422944 @default.
- W4362545247 hasRelatedWork W4323046910 @default.
- W4362545247 isParatext "false" @default.
- W4362545247 isRetracted "false" @default.
- W4362545247 workType "article" @default.